Pancreatic Cancer Research

ResearcherNingxia Medical University General HospitalActive in the last 2 years

Yongfeng Hui

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0001-1309-7767; OpenAlex author ID A5005468389. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 3

  1. PROK1 Induces Macrophage M2 Phenotype Conversion to Promote Pancreatic Cancer Progression by Activating the PI3K/AKT Pathway Via Interacting with PROKR2. Co-author DOI 10.1007/s12010-026-05772-0↗
  2. PI3K/AKT/mTOR pathway and its related molecules participate in PROK1 silence-induced anti-tumor effects on pancreatic cancer. Last author DOI 10.1515/biol-2022-0538↗
  3. miR‑32‑5p suppresses the proliferation and migration of pancreatic adenocarcinoma cells by targeting TLDC1. Co-author DOI 10.3892/mmr.2021.12392↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lan Ma · 1 shared paper, 2026 · strength 0.32
  2. Jianjun Song · 1 shared paper, 2026 · strength 0.32
  3. Fang Wang · 1 shared paper, 2026 · strength 0.32
  4. Yongqiang Hua · 1 shared paper, 2023 · strength 0.18
  5. Feng Wang · 1 shared paper, 2023 · strength 0.18
  6. Fei Peng · 1 shared paper, 2023 · strength 0.18
  7. Guozhong Zhao · 1 shared paper, 2021 · strength 0.12
  8. Weijie Yao · 1 shared paper, 2021 · strength 0.12
  9. Zuozheng Wang · 1 shared paper, 2021 · strength 0.12
  10. Peng Yuan · 1 shared paper, 2021 · strength 0.12
  11. Bendong Chen Chen · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.